Servier: Lipertance Combination drug for the treatment of arterial hypertension and dyslipidemia

Main article: Arterial hypertension (high pressure)

2022: Release of Lipertans for the treatment of arterial hypertension and dyslipidemia

Servier presented on September 30, 2022 the drug Lipertans (amlodipine + atorvastatin + perindopril) for the treatment of arterial hypertension and dyslipidemia. The drug product in a dosage of 5 mg + 10 mg + 5 mg is already available to Russian patients. Lipertance in dosages of 5 mg + 20 mg + 5 mg and 5 mg + 20 mg + 10 mg will appear in Russian pharmacies by the end of October 2022.

Illustration: white-medicine.com

As of September 30, 2022, the drug Lipertans is a fixed combination of an angiotensin-converting enzyme inhibitor (perindopril), a calcium channel antagonist (amlodipine) and one of the most studied statins (atorvastatin). The components of Lipertans have a favorable safety profile and are widely used in clinical practice for both primary and secondary prevention of cardiovascular disease.

Arterial hypertension (AH), the prevalence of which among the adult population is 30-45%, is one of the most important risk factors for progression warmly-vascular diseases. AH also plays a crucial role in the clinical course of IBS, peripheral artery disease, stroke chronic heart failure and chronic disease. kidneys Dyslipidemia significantly affects development atherosclerosis and is a key predictor of cardiovascular complications in patients with AH. The prevalence of the combination of dyslipidemia and AH is approximately 40%.

The accumulated extensive evidence base suggests that the clinical efficacy of controlling AH and reducing the risk of cardiovascular events achieved using the combination of perindopril and amlodipine can be significantly enhanced with the additional administration of lipid-lowering therapy, in particular atorvastatin.

Combination therapy, which includes amlodipine, atorvastatin, and perindopril, is indicated in a wide range of patients in whom AH is combined with atherosclerotic CVD or hypercholesterolemia. The three-component composition, convenience of use, good tolerability of the drug create prerequisites for achieving an optimal therapeutic effect. In addition, administration of fixed combination medications is the preferred regimen for improving adherence in accordance with current Russian guidelines for the management of patients with AH. noted Professor Yu.A. Karpov.

Also at the conference, Professor Karpov presented a report on the results of the ASCOT LLA6 study: in this study, patients with AH and at least three cardiovascular risk factors (with total blood cholesterol ≤6,5 mmol/L)  were prescribed atorvastatin at a dose of 10 mg/day in addition to combined antihypertensive therapy. or placebo. The average duration of follow-up was 3.3 years. In the atorvastatin group, there was a statistically significant reduction in the incidence of primary endpoint events (non-fatal myocardial infarction and IBS death) by 36% (p = 0.0005), all cardiovascular events by 21% (p = 0.0005), all coronary events by 29% (p = 0.0005), fatal and non-fatal strokes by 27% (p = 0.02).

In Russia, according to a number of studies, about half of patients with AH do not comply with the prescribed therapy, and 60% stop taking drugs within the first year, which increases the frequency of hospitalization and the risk of premature death. The use of Lipertans - a fixed combination of drugs in one tablet - will reduce the number of concomitant drugs, thereby improving adherence to treatment and increasing its effectiveness. told Yana Rostovtseva, managing director of Servier in Russia.